Find and Pitch Jounalists, Get Your Story Covered

Tags: leptin plasma alzheimer disease alzheimer's disease amyloid

	Profile	Recent Articles on Subject
1	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Some Disease Burden of Obesity Requires Pharmacotherapy, Not Just Lifestyle Interventions - 15 days ago Teva Launches Generic Formulation of Liraglutide in US - 5 months ago Compounded, Counterfeit Semaglutide Poses Severe Risk to Patients - 6 months ago Investigational GLP-1 Medication Found to Reduce Body Weight - 9 months ago Proposed Biosimilar Liraglutide Shows Non-Inferiority to Reference Drug for Type 2 Diabetes - 10 months ago
2	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - 19 days ago More evidence on GLP-1s and opioid addiction - 26 days ago STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 2 months ago STAT+: Lilly’s Zepbound slashed risk of developing diabetes - 3 months ago Can you get satiety with GLP-1s without the nausea? - 4 months ago STAT+: Pfizer says it will advance once-daily GLP-1 pill after all - 4 months ago STAT+: Amgen goes all in on injectable obesity drug as it scraps early-stage pill - 6 months ago STAT+: Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label - 8 months ago STAT+: Liver disease MASH is next target for obesity drugs in development - 9 months ago STAT+: What comes after Wegovy? The quest to eradicate obesity - 11 months ago STAT+: Wegovy may have another helpful trick: fighting inflammation via the brain, study finds - 11 months ago STAT+: Even as Wegovy rides high, interest surges in weight loss drugs that preserve muscle - 12 months ago Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound - about 1 year ago STAT+: Our expensive obesity drugs are worth it, Novo Nordisk and Eli Lilly argue in raft of studies - about 1 year ago
3	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - 19 days ago STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more - 3 months ago STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more - 4 months ago STAT+: Pharmalittle: We’re reading about weight loss drugs, a cell therapy for melanoma, and more - 9 months ago STAT+: Pharmalittle: More U.S. states and cities are suing insulin makers; Biden looks to boost U.S. drug manufacturing amid shortages - 12 months ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - about 1 year ago
4	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - 19 days ago
5	Michelle Starr Science Alert Senior Journalist at Science Alert. science journalism	Boosting Access to Weight-Loss Drugs Could Save Thousands of Lives - 19 days ago
6	Kristen Monaco MedPage Today	Liraglutide Helped Cut BMI in Kids With Obesity as Young as 6 - 2 months ago Zepbound Can Prevent Diabetes; Menopause and Cognition; Tandem's Insulin Pump Update - 3 months ago Early-Stage GLP-1 Win in Obesity; An Argument for BMI's Value; Insulin Supply Issues - 4 months ago Few Stick With Ozempic; Pfizer Making Daily GLP-1; Once-Weekly Insulin Turned Down - 4 months ago Novel Drug Better Than Wegovy? New Endocrine Society Prez; Knockoff Tirzepatide Woes - 8 months ago Phase II Wins, Losses for Obesity Drugs; More Positive Veozah Data; Walking Off T2D - 11 months ago Mounjaro vs Ozempic for Obesity; New Microwave Ablation System; GAHT Erythrocytosis - 12 months ago Tirzepatide Wins FDA Approval for Weight Loss - about 1 year ago Hospitalizations With Fake Ozempic; Vosoritide OK'd for All Ages; Mounjaro for Kids? - about 1 year ago
7	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 2 months ago STAT+: Eli Lilly reports tirzepatide MASH success during Q4 earnings - 9 months ago STAT+: Even as Wegovy rides high, interest surges in weight loss drugs that preserve muscle - 12 months ago
8	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Pharmalittle: We’re watching positive Zepbound cardiovascular data, a move to take 23andMe private, and more - 3 months ago European regulators find no evidence of link between new obesity medicines and suicidal thoughts - 7 months ago STAT+: Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH - 9 months ago STAT+: What comes after Wegovy? The quest to eradicate obesity - 11 months ago STAT+: New weight loss drugs have proven their effectiveness. Now researchers want to know how to best use them - 11 months ago
9	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Pfizer says it will advance once-daily GLP-1 pill after all - 4 months ago STAT+: Eli Lilly’s chief scientist on new obesity drug data, gene editing, and a potential new heart drug - 12 months ago
10	Adam Spatacco Motley Fool Community for top investors. Investingcommunity	Move Over, Mounjaro. Eli Lilly Has Another Blockbuster in the Making - 6 months ago

Journalists covering leptin